Bonne Bell Therapy Lip Maintenance SPF30+

Երկիր: Ավստրալիա

Լեզու: անգլերեն

Աղբյուրը: Department of Health (Therapeutic Goods Administration)

Ակտիվ բաղադրիչ:

4-methylbenzylidene camphor,Butyl methoxydibenzoylmethane,octyl methoxycinnamate

Հասանելի է:

Aspire Brands Pty Ltd

INN (Միջազգային անվանումը):

4-methylbenzylidene camphor,Butyl methoxydibenzoylmethane,octyl methoxycinnamate

Դաս:

Medicine Listed

Տեղեկատվական թերթիկ

PANCURONIUM
BROMIDE INJECTION
B.P.
_Pancuronium Bromide_
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some of the
common questions people ask about
Pancuronium Bromide Injection. It
does not contain all the information
that is known about Pancuronium
Bromide Injection.
It does not take the place of talking to
your doctor or pharmacist.
All medicines have risks and
benefits. Your doctor will have
weighed the risks of you being given
Pancuronium Bromide Injection
against the benefits they expect it
will have for you.
IF YOU HAVE ANY CONCERNS ABOUT
BEING GIVEN THIS MEDICINE, ASK YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET.
You may need to read it again.
WHAT PANCURONIUM
BROMIDE INJECTION IS
FOR
Pancuronium Bromide Injection is
used to stop your muscles moving
during surgery or in intensive care.
It belongs to a group of medicines
called neuromuscular blockers,
which work by stopping messages
being sent from the nerves to the
muscles.
Your doctor will have explained why
you are being treated with
Pancuronium Bromide Injection.
FOLLOW ALL DIRECTIONS GIVEN TO YOU
BY YOUR DOCTOR CAREFULLY. THEY MAY
DIFFER FROM THE INFORMATION
CONTAINED IN THIS LEAFLET.
Your doctor may prescribe this
medicine for another use. Ask your
doctor if you want more information.
Pancuronium Bromide Injection is
not addictive.
BEFORE YOU ARE GIVEN
PANCURONIUM BROMIDE
INJECTION
You may already have been given
Pancuronium Bromide Injection.
Your doctor will have considered the
situation carefully and decided to use
it. However, if any of the following
applies to you, tell your doctor
immediately.
_WHEN YOU MUST NOT USE IT_
YOU MUST NOT BE GIVEN
PANCURONIUM BROMIDE INJECTION IF
YOU:
•
ARE SENSITIVE TO PANCURONIUM
BROMIDE OR TO THE BROMIDE ION
•
HAVE AN ALLERGY TO ANY
INGREDIENT LISTED AT THE END OF
THIS LEAFLET OR ANY OTHER RELATED
MEDICINES.
If you have an allergic reaction, you
may get a skin rash, hay fever,
asthma or feel faint.
YOU SHOULD NOT BE GIVEN
PANCURONIUM BROMIDE INJECTION IF
YOU ARE PREGNANT OR BREAST

Ապրանքի հատկությունները

1 of 11
AUSTRALIAN PRODUCT INFORMATION
PANCURONIUM INJECTION BP
(PANCURONIUM BROMIDE)
1
NAME OF THE MEDICINE
Pancuronium bromide.
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
2 mL sterile solution of pH 3.5 – 4.2 containing 4 mg of pancuronium
bromide.
Excipients with known effect: sodium chloride, sodium acetate, sodium
hydroxide.
For the full list of excipients, see Section 6.1.
3
PHARMACEUTICAL FORM
Injection solution. Clear, colourless solution.
A sterile solution of pancuronium bromide suitable for
IV injection.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
An adjunct to surgical anaesthesia to induce skeletal muscle
relaxation to facilitate operative
manipulations. The necessary conditions for intubation can be achieved
with pancuronium bromide
alone or following suxamethonium.
Pancuronium bromide is also indicated to promote mechanical
ventilation by reducing or
eliminating spontaneous breathing effort in intensive care patients.
4.2
DOSE AND METHOD OF ADMINISTRATION
The following dosage information is a guide only.
Pancuronium bromide is given by intravenous administration. The dosage
should be individualised
for each patient as there is wide variation in individual response to
muscle relaxants. The potential
effect of the anaesthetic or any other concomitant drug, clinical
state of the patient and the
anticipated duration of the neuromuscular block must be taken into
account when the dosage is
determined.
It is recommended that a peripheral nerve stimulator be used to
monitor response to pancuronium
bromide to minimise the risk of overdosage.
Since potent inhalation agents or prior administration of
suxamethonium enhance the intensity of
blockade and duration of action of pancuronium bromide, these factors
should be considered when
selecting initial and incremental dosage.
In heavy or obese patients doses of pancuronium based on mg/kg may
lead to overdosage.
For use in one patient on one occasion only. Discard any unused
contents of an opened ampoule.
2 of 11
ADULTS (AGED 12 YEARS AND ABOVE)
Initial